Seres Therapeutics Inc（MCRB）资讯与事件MCRBSeres Therapeutics Inc

Seres Therapeutics Files $300M Mixed Securities Shelf

Seres Therapeutics files $300M mixed securities shelf

U.S. Stock Futures Lower as Oil Prices Surge

Stock futures are lower ahead of the opening bell as renewed fighting between the U.S. and Iran sends oil prices sharply higher. President Donald Trump said a ceasefire aimed at ending the conflict was "over," fueling concerns that last month's deal has unraveled.Brent and West Texas Intermediate crude have climbed more than 5% on fears that renewed hostilities and attacks near the Strait of Hormuz could disrupt global energy supplies. The rally is boosting shares of oil producers, while weighing on airlines, cruise operators and other travel-related stocks that are sensitive to higher fuel costs.Technology is also under pressure as semiconductor stocks continue to struggle. The Philadelphia Semiconductor Index has extended its recent decline, reflecting growing investor caution after the sector's outsized gains earlier this year.Investors will also be watching this afternoon's release of the Federal Reserve's June meeting minutes for additional insight into policymakers' views on inflation and interest rates. However, with oil prices climbing and geopolitical tensions escalating, markets may place greater emphasis on developments in the Middle East than on backward-looking Fed commentary.In pre-market trading, S&P 500 futures fell 0.49%, Nasdaq futures fell 0.60% and Dow futures fell 0.79%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Beazer Homesup 12% after Dream Finders Homessubmitted a revised proposal to the board of directors of the company to acquire all outstanding shares of Beazer in an all-cash transaction for $32 per share, a nearly 24% increase to its prior proposalSeres Therapeuticsup 7% after reporting results from an investigator-sponsored trial evaluating SER-155 in patients with irECBroadcomup 1% after Appleannounced a new multiyear commitment with the company to design and produce custom silicon components and wireless connectivity technologies for a wide range of Apple productsUP AFTER EARNINGS -Helen of Troyup 7%Palladyne AIup 4%Sono-Tekup 1%LOWER -Riviandown 5% after its 75M share equity offering priced at $15.50Bath & Body Worksdown 4% after Goldman Sachs downgraded the stock to Sell with a price target of $19, down from $23Estee Lauderdown 2% after announcing expectations to record cumulative restructuring and other charges of approximately $1.75B in connection with initiatives approved since inception of the restructuring program through June 30

Seres Therapeutics Announces SER-155 Clinical Trial Results

Seres Therapeutics announced top-line results from an investigator-sponsored trial evaluating SER-155 in patients with irEC. The study, conducted at MSK, evaluated SER-155 in 15 patients with moderate-to-severe irEC, which affects approximately 25% of all immune checkpoint inhibitor therapy recipients in the U.S. Clinical guidelines for these patients stipulate halting of ICI cancer treatment and initiation of systemic immunosuppressive corticosteroids, which are associated with clinically meaningful toxicities and other negative consequences, including: systemic immunosuppression, increased infection risk, metabolic complications, and potential interference with cancer treatment. There remains a significant unmet need for systemic immunosuppressive-free therapeutic approaches that reduce gastrointestinal inflammation and diarrhea and may allow patients who develop irEC to avoid disruption of their life-saving ICI cancer treatment. Participants in the study were on a wide range of ICI types, including PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, LAG-3 inhibitor, and combinations thereof. The promising study results support continued development of SER-155 to treat irEC. Following SER-155 dosing, 12 of 15 participants achieved an immunosuppressive-free clinical response at Day 15, the primary endpoint, defined as at least a 1-grade improvement in diarrhea symptoms without immunosuppressive therapy. Notably, 8 of these 12 responders achieved greater than or equal to a 2-grade improvement in diarrhea symptoms without immunosuppressive therapy at Day 15. At Day 15, 5 of 15 participants achieved immunosuppressive-free complete clinical remission, defined as total resolution of diarrhea symptoms to Grade 0, without immunosuppressive therapy. At Day 43, 5 of 15 participants maintained immunosuppressive-free clinical response, and, notably, 2 of 15 participants maintained immunosuppressive-free complete clinical remission. All 12 participants with immunosuppressive-free clinical response at Day 15 had the same, or better, diarrhea grade at Day 43. As noted, 5 maintained immunosuppressive-free clinical response at Day 43. The other seven were treated with non-systemically acting, gastrointestinal-targeted immunosuppressives after Day 15. SER-155 was generally well tolerated through Day 43, with no safety concerns identified, consistent with the outcome in Seres' Phase 1b study of SER-155 in participants undergoing allogeneic hematopoietic cell transplantation. There were no serious adverse events assessed as related to SER-155 and no bloodstream infections reported in the study through Day 43. Two participants experienced 2 non-serious adverse events each, assessed as possibly related to vancomycin and SER-155. All 4 adverse events were moderate in severity and were resolved. SER-155 bacterial strain engraftment was robust, with the majority of SER-155 strains observed across the study participants, and with kinetics, magnitude, and durability comparable to that observed in prior Seres clinical studies. Translational biomarkers of gastrointestinal inflammation and of mucosal epithelial barrier integrity, which were elevated in participants at baseline, prior to SER-155 dosing, both showed decreases post SER-155 treatment, with statistically significant reductions achieved by Day 43, reflecting improvement in two mechanistically linked dimensions of irEC disease. Data suggest that administration of SER-155 led to improvement in mucosal epithelial barrier integrity, providing support for potential further development in multiple other inflammatory and immune diseases.